<DOC>
	<DOCNO>NCT01175785</DOCNO>
	<brief_summary>This phase II trial study safety potential efficacy infuse non-human leukocyte antigen match ex vivo expand cord blood progenitor one two unmanipulated umbilical cord blood unit transplantation follow condition fludarabine phosphate , cyclophosphamide total body irradiation , immunosuppression cyclosporine mycophenolate mofetil patient hematologic malignancy . Chemotherapy , fludarabine phosphate cyclophosphamide , total-body irradiation give umbilical cord blood transplant stop growth leukemia cell work prevent patient 's immune system reject donor 's stem cell . The healthy stem cell donor 's umbilical cord blood help patient 's bone marrow make new red blood cell , white blood cell , platelet . It may take several week new blood cell grow . During period time , patient increase risk bleed infection . Faster recovery white blood cell may decrease number severity infection . Studies show count recover quickly cord blood cell give transplant . We develop way grow `` expand '' number cord blood cell lab cell available transplant . We study find whether give expanded cell along one two unexpanded cord blood unit safe use expand cell decrease time take white blood cell recover transplant . We study time take blood count recover , two three cord blood unit make patient 's new blood system , quickly immune system cell return .</brief_summary>
	<brief_title>Infusion Off-the-Shelf Expanded Cord Blood Cells Augment Cord Blood Transplant Patients With Hematologic Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Examine safety toxicity ex vivo expand cord blood cell infuse off-the-shelf non-human leukocyte antigen ( HLA ) match product goal provide rapid transient myelopoiesis set single double umbilical cord blood transplant . II . Examine vivo persistence ex vivo expand cord blood product . The kinetics durability hematopoietic reconstitution determine relative contribution engraftment expand cord blood product unmanipulated cord blood unit ( ) early long-term engraftment determine frequent determination donor chimerisms peripheral blood . SECONDARY OBJECTIVES I . Estimate incidence severity acute chronic graft-versus-host-disease ( GVHD ) patient receive off-the-shelf ex vivo expand cryopreserved cord blood cell . II . Estimate incidence transplant related mortality day 100 . III . Estimate incidence malignant relapse probability overall event-free survival 1 2 year post transplant . IV . Obtain preliminary data incidence infections/viral reactivation start condition 100 day post transplant 6 month , 1 year 2 year post transplant possible . V. Obtain preliminary data phenotype function immune cell recover patient receive expand unmanipulated cord blood graft . VI . Examination possible immunologic factor lead emergence dominant unit . OUTLINE : MYELOABLATIVE CONDITIONING : Patients receive fludarabine phosphate intravenously ( IV ) 1 hour day -8 -6 cyclophosphamide IV day -7 -6 . Patients undergo total-body irradiation ( TBI ) twice daily day -4 -1 . TRANSPLANTATION : Patients undergo unmanipulated single- double-unit umbilical cord blood transplantation day 0 receive ex vivo-expanded cord blood progenitor cell IV 4 hour follow last unmanipulated cord blood infusion . GVHD PROPHYLAXIS : Patients initially receive cyclosporine ( CSP ) IV 1 hour begin day -3 . CSP may give orally ( PO ) patient tolerate oral medication normal gastrointestinal transit time . CSP give day 100 , may taper day 101 graft versus host disease . Patients also receive mycophenolate mofetil ( MMF ) IV every 8 hour day 0 7 may receive MMF PO begin day 8 30 . MMF continue minimum 30 day 7 day blood count recover whichever later . If evidence acute GVHD donor cluster differentiation ( CD ) 3 engraftment least 50 % one donor MMF may taper .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Acute myeloid leukemia : High risk complete response ( CR ) 1 evidence precede myelodysplastic syndrome ( MDS ) , high risk cytogenetics ( example , monosomy 5 7 , define refer institution treatment protocol ) , &gt; = 2 cycle obtain CR , erythroblastic megakaryocytic leukemia ; &gt; = CR2 All patient must CR define hematologic recovery &lt; 5 % blast morphology within bone marrow cellularity &gt; = 15 % Patients adequate marrow/biopsy specimen obtain determine remission status morphologic assessment , fulfil criterion remission flow cytometry , recovery peripheral blood count circulate blast , and/or normal cytogenetics ( applicable ) may still eligible ; reasonable attempt must make obtain adequate specimen morphologic assessment , include possible repeat procedure ; patient must discuss Principal Investigator , Colleen Delaney prior enrollment Acute lymphoblastic leukemia : High risk CR1 [ example , limit : ( 9 ; 22 ) , ( 1 ; 19 ) , ( 4 ; 11 ) mixed lineage leukemia ( MLL ) rearrangement , hypodiploid ] Greater 1 cycle obtain CR &gt; = CR2 All patient must CR define hematologic recovery &lt; 5 % blast morphology within bone marrow cellularity &gt; = 15 % Patients adequate marrow/biopsy specimen obtain determine remission status morphologic assessment , fulfil criterion remission flow cytometry , recovery peripheral blood count circulate blast , and/or normal cytogenetics ( applicable ) may still eligible ; reasonable attempt must make obtain adequate specimen morphologic assessment , include possible repeat procedure ; patient must discuss Principal Investigator , Colleen Delaney prior enrollment Chronic myelogenous leukemia exclude refractory blast crisis ; eligible first chronic phase ( CP1 ) patient must fail intolerant imatinib mesylate Myelodysplasia ( MDS ) International Prognostic Scoring System ( IPSS ) intermediate 2 ( Int2 ) high risk ( i.e. , refractory anemia excess myeloblast [ RAEB ] , refractory anemia excess blast transformation [ RAEBT ] ) refractory anemia severe pancytopenia high risk cytogenetics ; blast must &lt; 10 % representative bone marrow aspirate morphology Karnofsky ( &gt; = 16 year old ) &gt; = 70 % Lansky ( &lt; 16 year old ) &gt; = 50 % Calculated creatinine clearance must &gt; 60 mL serum creatinine = &lt; 2 mg/dL ( adult ) Calculated creatinine clearance must &gt; 60 mL/min ( child &lt; 18 year old ) Total serum bilirubin must &lt; 3 mg/dl Transaminases must &lt; 3 x upper limit normal Diffusion capacity lung carbon monoxide ( DLCO ) correct &gt; 50 % normal For pediatric patient unable perform pulmonary function test , oxygen ( O2 ) saturation &gt; 92 % room air Left ventricular ejection fraction &gt; 45 % OR shorten fraction &gt; 26 % Ability understand willingness sign write informed consent document Uncontrolled viral bacterial infection time study enrollment Active recent ( prior 6 month ) invasive fungal infection without infectious disease ( ID ) consult approval History human immunodeficiency virus ( HIV ) infection Pregnant breastfeeding If = &lt; 18 year old , prior myeloablative transplant within last 6 month If &gt; 18 year old prior myeloablative allotransplant autologous transplant Extensive prior therapy include &gt; 12 month alkylator therapy &gt; 6 month alkylator therapy extensive radiation</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>